Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.

This is an extension study to evaluate the long-term safety, tolerability, and efficacy of
two dose strengths of dalfampridine-ER twice daily tablets when administered for at least 12
months to subjects with chronic post-ischemic stroke walking deficits who have completed the
controlled, double-blind Study DALF-PS-1016.

Key Inclusion Criteria:

- Completion of the DALF-PS-1016 study

- Providing informed consent to continue into the DALF-PS-1029 long-term extension study

- Sufficient ambulatory ability to independently complete the Two Minute Walk Test
(2MinWT) and 10 Meter Walk Test (10MWT) at the time of enrollment into the extension
study

Key Exclusion Criteria:

- Seizures, new onset strokes (or other significant neurological event precluding
long-term continuation) occurring during the antecedent DALF-PS-1016 study

- Calculated creatinine clearance of ≤ 50 mL/minute at the time of enrollment into the
long-term extension study